title: Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma.
abstract: Radical surgery (RS) with adjuvant chemotherapy (AC) or radiotherapy has been conventionally used for patients with advanced urothelial carcinoma (AUC). Recent research has indicated that systemic neoadjuvant chemotherapy (NC) with RS yields better outcomes than RS alone for patients with locally advanced bladder cancer. However, there are no reports indicating whether NC or AC would be beneficial for patients with AUC. The present study compared the survival rate for AUC patients receiving NC or AC. A retrospective analysis was conducted using data for 64 patients with AUC who underwent RS and systemic chemotherapy at our institution between March 2002 and March 2011. Of the 64 patients, 30 received NC before RS and 34 received RS followed by systemic AC. Pathologic stages (p=0.002), grades (p=0.018) and lymphovascular invasion (p=0.047) were significantly lower in the patients who received NC first than in those who received RC first. Furthermore, analysis of the surgical specimens revealed that 26.7% of patients who received NC before RS had complete remission. There were no significant differences in demographic data, surgical complications, and chemotoxicity between the two patient groups. The progression-free survival (PFS) and overall survival (OS) of patients who received initial NC were significantly better than those of patients who received initial RC (p=0.002 and 0.018, respectively). Our results indicate that NC administration before RS significantly improved the PFS and OS of AUC patients, without increasing surgical complications and chemotoxicity. Further prospectively controlled trials need to be conducted to confirm the effectiveness of NC for AUC patients.
authors.affiliation: Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
authors.forename: Chia-Chun
authors.initials: CC
authors.lastname: Tsai
authors.forename: Chun-Hsiung
authors.initials: CH
authors.lastname: Huang
authors.forename: Chun-Nung
authors.initials: CN
authors.lastname: Huang
authors.forename: Wen-Jeng
authors.initials: WJ
authors.lastname: Wu
authors.forename: Hsin-Chih
authors.initials: HC
authors.lastname: Yeh
authors.forename: Wei-Ming
authors.initials: WM
authors.lastname: Li
authors.forename: Ching-Chia
authors.initials: CC
authors.lastname: Li
authors.forename: Mei-Hui
authors.initials: MH
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019459:Urothelium / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine
references.citation: Eur Urol. 1996;29(3):266-70; discussion 271
references.pmid: 8740029
references.citation: Urology. 1998 Oct;52(4):594-601
references.pmid: 9763077
references.citation: J Clin Oncol. 1994 Jul;12(7):1394-401
references.pmid: 8021730
references.citation: BJU Int. 2010 Aug;106(4):489-92
references.pmid: 20039869
references.citation: Cancer Sci. 2006 Sep;97(9):821-8
references.pmid: 16822297
references.citation: Anticancer Res. 2011 Oct;31(10):3503-6
references.pmid: 21965769
references.citation: Eur Urol. 2008 Nov;54(5):1127-34
references.pmid: 18243511
references.citation: J Urol. 2005 Dec;174(6):2138-42, discussion 2142-3
references.pmid: 16280744
references.citation: Ann Surg. 2009 Aug;250(2):177-86
references.pmid: 19638919
references.citation: Nat Clin Pract Urol. 2006 Jun;3(6):327-40
references.pmid: 16763645
references.citation: Cancer. 2009 Sep 15;115(18):4104-9
references.pmid: 19517476
references.citation: Lancet. 2003 Jun 7;361(9373):1927-34
references.pmid: 12801735
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2781-9
references.pmid: 15199091
references.citation: Br J Urol. 1993 Mar;71(3):274-8
references.pmid: 8477313
references.citation: Eur Urol. 2011 Apr;59(4):584-94
references.pmid: 21269756
references.citation: J Support Oncol. 2003 Nov-Dec;1(4 Suppl 2):18-24
references.pmid: 15346996
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Urol. 2009 Sep;182(3):900-6
references.pmid: 19616245
references.citation: Eur Urol. 2009 Apr;55(4):761-9
references.pmid: 19144456
references.citation: J Urol. 2002 Jan;167(1):352-6
references.pmid: 11743355
references.citation: J Clin Oncol. 2000 Sep;18(17):3068-77
references.pmid: 11001674
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references.pmid: 12903007
references.citation: Cancer. 2010 Jul 1;116(13):3127-34
references.pmid: 20564621
references.citation: J Urol. 1996 Feb;155(2):495-9; discussion 499-500
references.pmid: 8558644
references.citation: N Engl J Med. 2003 Aug 28;349(9):859-66
references.pmid: 12944571